AU682317B2 - Heteroaryl compounds used as pharmaceuticals - Google Patents

Heteroaryl compounds used as pharmaceuticals Download PDF

Info

Publication number
AU682317B2
AU682317B2 AU49764/93A AU4976493A AU682317B2 AU 682317 B2 AU682317 B2 AU 682317B2 AU 49764/93 A AU49764/93 A AU 49764/93A AU 4976493 A AU4976493 A AU 4976493A AU 682317 B2 AU682317 B2 AU 682317B2
Authority
AU
Australia
Prior art keywords
compound
formula
document
hydrogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49764/93A
Other languages
English (en)
Other versions
AU4976493A (en
Inventor
Laramie Mary Gaster
Francis David King
Keith Raymond Mulholland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4976493A publication Critical patent/AU4976493A/en
Application granted granted Critical
Publication of AU682317B2 publication Critical patent/AU682317B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU49764/93A 1992-09-10 1993-09-07 Heteroaryl compounds used as pharmaceuticals Ceased AU682317B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929219163A GB9219163D0 (en) 1992-09-10 1992-09-10 Pharmaceuticals
GB9219163 1992-09-10
PCT/GB1993/001895 WO1994005654A1 (en) 1992-09-10 1993-09-07 Heteroaryl compounds used as pharmaceuticals

Publications (2)

Publication Number Publication Date
AU4976493A AU4976493A (en) 1994-03-29
AU682317B2 true AU682317B2 (en) 1997-10-02

Family

ID=10721705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49764/93A Ceased AU682317B2 (en) 1992-09-10 1993-09-07 Heteroaryl compounds used as pharmaceuticals

Country Status (13)

Country Link
US (2) US5620992A (OSRAM)
EP (1) EP0659183A1 (OSRAM)
JP (1) JPH08501293A (OSRAM)
KR (1) KR950703557A (OSRAM)
CN (1) CN1040645C (OSRAM)
AU (1) AU682317B2 (OSRAM)
CA (1) CA2144423A1 (OSRAM)
GB (1) GB9219163D0 (OSRAM)
MX (1) MX9305510A (OSRAM)
NZ (1) NZ255535A (OSRAM)
TW (1) TW268006B (OSRAM)
WO (1) WO1994005654A1 (OSRAM)
ZA (1) ZA936613B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
EP0664805A1 (en) * 1992-10-13 1995-08-02 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht 4? receptor antagonists
EP0664794A1 (en) * 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
GB9312348D0 (en) * 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
UA50748C2 (uk) * 1995-11-09 2002-11-15 Санофі-Сентелябо Похідні 5-феніл-3(піперидин-4-іл)-1,3,4-оксадіазол-2(3н)ону та фармацевтична композиція
FR2741070B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
CA2340952C (en) 1998-09-10 2009-12-08 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
JP4916878B2 (ja) 2003-06-19 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５ｈｔ４−拮抗薬としてのアミノスルホニル置換４−（アミノメチル）−ピペリジンベンズアミド
CN103420989B (zh) * 2012-05-15 2016-03-23 华中科技大学 苯并二噁烷类衍生物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2176785A (en) * 1985-06-19 1987-01-07 Astra Laekemedel Ab Annellated benzamide derivatives
EP0407137A2 (en) * 1989-07-03 1991-01-09 Yoshitomi Pharmaceutical Industries, Ltd. Benzazine compounds and pharmaceutical uses thereof
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186135A (en) * 1976-08-04 1980-01-29 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation
US4268512A (en) * 1976-08-04 1981-05-19 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
GB9027098D0 (en) * 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
US5580885A (en) * 1991-09-12 1996-12-03 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
JPH05194406A (ja) * 1991-11-12 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 新規アミド化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2176785A (en) * 1985-06-19 1987-01-07 Astra Laekemedel Ab Annellated benzamide derivatives
EP0407137A2 (en) * 1989-07-03 1991-01-09 Yoshitomi Pharmaceutical Industries, Ltd. Benzazine compounds and pharmaceutical uses thereof
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Also Published As

Publication number Publication date
KR950703557A (ko) 1995-09-20
ZA936613B (en) 1994-05-16
CA2144423A1 (en) 1994-03-17
AU4976493A (en) 1994-03-29
US5620992A (en) 1997-04-15
EP0659183A1 (en) 1995-06-28
CN1089946A (zh) 1994-07-27
NZ255535A (en) 1996-10-28
GB9219163D0 (en) 1992-10-28
TW268006B (OSRAM) 1996-01-11
US5786372A (en) 1998-07-28
JPH08501293A (ja) 1996-02-13
CN1040645C (zh) 1998-11-11
MX9305510A (es) 1994-05-31
WO1994005654A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
EP0604494B1 (en) 5-ht4 receptor antagonists
US5872134A (en) 5-HT4 receptor antagonists
EP0667867A1 (en) Piperidine derivatives as 5-ht4 receptor antagonists
WO1993016072A1 (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
WO1994008995A1 (en) Heterocyclic condensed benzoic acid derivatives as 5-ht4 receptor antagonists
US5620992A (en) Heteroaryl compounds used as pharmaceuticals
US5726187A (en) N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
US5708174A (en) Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
WO1993008187A1 (en) Imidazopyridines and indolizines as 5-ht4 antagonists
WO1994017071A1 (en) Tricyclic heterocyclic compounds as 5-ht4 receptor antagonists
WO1994029298A1 (en) 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist
AU695034B2 (en) Condensed indole derivatives as 5-HT4-receptor antagonists
AP373A (en) Compounds having 5TH4 receptor antagonist activity.
WO1994019344A1 (en) Amide compounds with pharmacological activity
US6127379A (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
AU668102C (en) 5-HT4 receptor antagonists
HK1012347B (en) Condensed indole derivatives as 5-ht 4-receptor antagonists
WO2000017207A1 (en) 3,4-dihydro -n-[[1-(3 -hydroxybutyl) -4-piperidinyl] methyl] -2h-[1,3] oxazino[3, 2-a]indole -10-carboxamide as 5-ht(4) receptor antagonist
HK1023560A1 (en) N-(1-nbutyl-4-piperidyl)methyl-3,4-dihydro-2h-1,3 oxazino 3,2-a indole-10-carboxamide or a pharmaceutically acceptable salt thereof
HK1023560B (en) N-(1-nbutyl-4-piperidyl)methyl-3,4-dihydro-2h-1,3 oxazino 3,2-a indole-10-carboxamide or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired